Jeff – on you recommendation - . ICANN should have a thorough screening process to pick its evaluators/panelists and deference to their determinations should be given.
Do we know what the screening process was last go around? For example – how was the Economist Intelligence Unit selected? Was there an RFP issued? If so what were those terms?
CPE was a particularly painful exercise for more than a few applicants so yes – I’m sort of picking on that one but it would be illustrative to the others. I do know there was a tender process for the Independent Objector.
From: Gnso-newgtld-wg <gnso-newgtld-wg-bounces@icann.org>
On Behalf Of Jeff Neuman
Sent: Tuesday, October 15, 2019 9:25 AM
To: gnso-newgtld-wg@icann.org
Subject: [Gnso-newgtld-wg] Appeals Standard of Review
All,
One of the remaining topics for Appeals is to determine what the standard of review should be. The choices discussed are “De Novo” or “Clearly Erroneous.”
In theory it could be possible to have different standards of review depending on what is the issue being appealed. For example, for Conflicts of Interest determinations, we could state that such an appeal would be on a
De Novo standard, but for all other appeals, Clearly Erroneous. As a reminder, here are the different types of appeals:
My personal recommendation is that all appeals except for the Conflict of Interest appeals have a “Clearly Erroneous” standard. Conflict of Interests should be reviewed
under a De Novo Standard. To review anything else De Novo would be incredibly time consuming, costly, and could substantially delay applications. ICANN should have a thorough screening process to pick its evaluators/panelists and deference to
their determinations should be given. But determinations of Conflict of Interest seem to me to be appropriate for a De Novo standard because the original determination could be made by the party against whom the assertion of a conflict is made.
Thoughts?
Jeff Neuman
Senior Vice President
Com Laude | Valideus
1751 Pinnacle Drive
Suite 600, McLean
VA 22102, USA
M: +1.202.549.5079
D: +1.703.635.7514
E:
jeff.neuman@comlaude.com
www.comlaude.com
![]()
The contents of this email and any attachments are confidential to the intended recipient. They may not be disclosed, used by or copied in any way by anyone other than the intended recipient. If you have received this message in error,
please return it to the sender (deleting the body of the email and attachments in your reply) and immediately and permanently delete it. Please note that the Com Laude Group does not accept any responsibility for viruses and it is your responsibility to scan
or otherwise check this email and any attachments. The Com Laude Group does not accept liability for statements which are clearly the sender's own and not made on behalf of the group or one of its member entities. The Com Laude Group includes Nom-IQ Limited
t/a Com Laude, a company registered in England and Wales with company number 5047655 and registered office at 28-30 Little Russell Street, London, WC1A 2HN England; Valideus Limited, a company registered in England and Wales with company number 06181291 and
registered office at 28-30 Little Russell Street, London, WC1A 2HN England; Demys Limited, a company registered in Scotland with company number SC197176, having its registered office at 33 Melville Street, Edinburgh, Lothian, EH3 7JF Scotland; Consonum, Inc.
dba Com Laude USA and Valideus USA, headquartered at 1751 Pinnacle Drive, Suite 600, McLean, VA 22102, USA; Com Laude (Japan) Corporation, a company registered in Japan having its registered office at Suite 319,1-3-21 Shinkawa, Chuo-ku, Tokyo, 104-0033, Japan.
For further information see www.comlaude.com